<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">KANAMYCIN</span><br/>(kan-a-mye'sin)<br/><span class="topboxtradename">Kantrex<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">aminoglycoside</span><br/><b>Prototype: </b>Gentamicin<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>75 mg, 500 mg; 1 g vials</p>
<h1><a name="action">Actions</a></h1>
<p>Broad-spectrum, aminoglycoside antibiotic derived from <i>Streptomyces kanamyceticus</i>. Usually bacteriocidal in action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Active against many gram-negative micro-organisms, especially <i>Acinetobacter, Escherichia coli, Enterobacter aerogenes, Klebsiella pneumoniae, Proteus</i> sp, and <i>Serratia marcescens</i>. Also effective against many strains of <i>Staphylococcus aureus,</i> but it is not the drug of choice. Inhibits growth of <i>Mycobacterium tuberculosis</i> in vitro.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Orally to reduce ammonia-producing bacteria in intestinal tract, as adjunctive treatment of hepatic coma, and for preoperative
         bowel antisepsis; parenterally for short-term treatment of serious infections; intraperitoneally after fecal spill during
         surgery; as irrigation solution; and as aerosol treatment. In conjunction with other drugs to treat tuberculosis in patients
         resistant to conventional therapy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to kanamycin or other aminoglycosides; history of drug-induced ototoxicity, preexisting hearing
         loss, vertigo, or tinnitus; long-term therapy; PO use in intestinal obstruction or ulcerative bowel lesions; intraperitoneally
         to patients under effects of inhalation anesthetics or skeletal muscle relaxants. Safety during pregnancy (category D) or
         lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired renal function; older adults, neonates, and infants (immature renal systems); myasthenia gravis; parkinsonian syndrome.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Preoperative Intestinal Antisepsis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 g q1h for 4 doses then q6h for 3672 h<br/><br/><span class="indicationtitle">Hepatic Coma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 812 g/d in divided doses<br/><br/><span class="indicationtitle">Serious Infection</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 15 mg/kg/d in equally divided doses q812h<br/><span class="rdage">Adult:</span> <span class="rdroute">Intraperitoneal</span> 500 mg diluted in 20 mL sterile water instilled through wound catheter <span class="rdroute">Inhalation</span> 250 mg diluted in 3 mL  NS administered per nebulizer q612h <span class="rdroute">Irrigation</span> 0.25% solution prn<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on a full or empty stomach.</li>
<li>Store capsules at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Administer IM injection deep into upper outer quadrant of gluteal muscle (often painful).</li>
<li>Observe sites daily for signs of irritation; rotate injection sites.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span>  Dilute each 500 mg with at least 100 mL NS, D5W, D5/NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Over 3060 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Cephalothin,</b>
<b>cephapirin,</b>
<b>chlorpheniramine,</b>
<b>colistimethate,</b>
<b>heparin,</b>
<b>hydrocortisone,</b>
<b>methohexital,</b>
<b>ampicillin,</b>
<b>carbenicillin,</b>
<b>methicillin,</b>
<b>penicillin,</b>
<b>mezlocillin,</b>
<b>piperacillin.</b>
<span class="incompattype"> Y-site:</span>
<b>Heparin,</b>
<b>methohexital.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store vials at 15°30° C (59°86° F) unless otherwise directed. Some vials may darken with time,
            but this does not affect potency. Discard partially used vials within 48 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">All:</span> Dose related. <span class="typehead">Body as a Whole:</span> Eosinophilia, maculopapular rash, pruritus, urticaria, drug fever, <span class="speceff-life">anaphylaxis</span>. <span class="typehead">CNS:</span> Dizziness, circumoral and other paresthesias, optic neuritis, peripheral neuritis, headache, restlessness, tremors, lethargy,
      convulsions; <span class="speceff-life">neuromuscular paralysis, respiratory depression</span> (rarely). <span class="typehead">Special Senses:</span> Deafness (can be irreversible), <span class="speceff-common">tinnitus, vertigo</span> or <span class="speceff-common">dizziness,</span> ataxia, nystagmus. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, appetite changes, abdominal discomfort, stomatitis, proctitis, malabsorption syndrome (with prolonged
      oral administration). <span class="typehead">Hematologic:</span> Anemia, increased or decreased reticulocytes, granulocytopenia, <span class="speceff-life">agranulocytosis</span>, thrombocytopenia, purpura. <span class="typehead">Urogenital:</span>
<span class="speceff-life">Nephrotoxicity</span>; hematuria, urine casts and cells, proteinuria; elevated serum creatinine and BUN. <span class="typehead">Other:</span> Superinfections; local pain; nodular formation at injection site. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Amphotericin B,</b>
<b>cisplatin,</b>
<b>methoxyflurane,</b>
<b>vancomycin</b> add to nephrotoxicity; <span class="classification">general anesthetics</span>, <span class="classification">skeletal muscle relaxants</span> add to neuromuscular blocking effects; <b>capreomycin</b> compounds ototoxicity and nephrotoxicity; <span class="classification">loop and thiazide diuretics</span> may increase risk of ototoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from GI tract; readily absorbed from peritoneal cavity, bronchial tree, and wounds. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Elimination:</span> 8090% excreted in urine within 24 h. <span class="typehead">Half-Life:</span> 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor baseline C&amp;S, urinalysis, and kidney function prior to initiation of therapy and periodically thereafter.
            Monitor serum sodium, potassium, calcium, and magnesium.
         </li>
<li>Notify physician immediately of signs of renal irritation: albuminuria, casts, red and white cells in urine, increasing BUN,
            and serum creatinine, decreasing creatinine clearance, oliguria, and edema.
         </li>
<li>Monitor peak and trough serum kanamycin concentrations: Assess peak specimen 3060 min after IM administration; 30 min
            after completion of a 3060 min IV infusion. Assess trough levels just before the next IM or IV dose.
         </li>
<li>Keep patient well hydrated to prevent chemical irritation of renal tubules.</li>
<li>Monitor I&amp;O. Report decrease in urine output or change in I&amp;O ratio.</li>
<li>Determine baseline weight and vital signs and monitor at regular intervals during therapy.</li>
<li>Report signs of superinfection (see Appendix F).</li>
<li>Monitor for hearing and balance problems; stop drug if ototoxicity occurs. Tinnitus is not a reliable index of ototoxicity
            in the very elderly. Risk of ototoxicity is high in patients with impaired renal function, older adults, poorly hydrated patients,
            and with therapy <img src="../images/special/greaterorequal.gif"/>5 d.
         </li>
<li>
            							Note: Deafness has occurred 27 d or more after termination of therapy in patients with impaired renal function.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report ototoxic symptoms such as dizziness, hearing loss, weakness, or loss of balance; drug may need to be discontinued.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>